Transmission dynamics of drug-resistant tuberculosis in Ningbo, China: an epidemiological and genomic analysis

Front Cell Infect Microbiol. 2024 Feb 7:14:1327477. doi: 10.3389/fcimb.2024.1327477. eCollection 2024.

Abstract

Background: Tuberculosis (TB), particularly drug-resistant TB (DR-TB), remains a significant public health concern in Ningbo, China. Understanding its molecular epidemiology and spatial distribution is paramount for effective control.

Methods: From December 24, 2020, to March 12, 2023, we collected clinical Mycobacterium tuberculosis (MTB) strains in Ningbo, with whole-genome sequencing performed on 130 MTB strains. We analyzed DR-related gene mutations, conducted phylogenetic and phylodynamic analyses, identified recent transmission clusters, and assessed spatial distribution.

Results: Among 130 DR-TB cases, 41% were MDR-TB, 36% pre-XDR-TB, 19% RR-TB, and 3% HR-TB. The phylogenetic tree showed that 90% of strains were Lineage 2 (Beijing genotype), while remaining 10% were Lineage 4 (Euro-American genotype). The spatial analysis identified hotspots of DR-TB in Ningbo's northern region, particularly in traditional urban centers. 31 (24%) of the DR-TB cases were grouped into 7 recent transmission clusters with a large outbreak cluster containing 15 pre-XDR-TB patients. Epidemiological analyses suggested a higher risk of recent DR-TB transmission among young adult patients who frequently visited Internet cafes, game rooms, and factories.

Conclusion: Our study provides comprehensive insights into the epidemiology and genetics of DR-TB in Ningbo. The presence of genomic clusters highlights recent transmission events, indicating the need for targeted interventions. These findings are vital for informing TB control strategies in Ningbo and similar settings.

Keywords: drug resistance; molecular epidemiology; phylodynamics; recent transmission; spatial distribution; tuberculosis; whole-genome sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • China / epidemiology
  • Drug Resistance, Multiple, Bacterial / genetics
  • Extensively Drug-Resistant Tuberculosis* / drug therapy
  • Genomics
  • Genotype
  • Humans
  • Microbial Sensitivity Tests
  • Mycobacterium tuberculosis*
  • Phylogeny
  • Tuberculosis, Multidrug-Resistant* / epidemiology
  • Tuberculosis, Multidrug-Resistant* / microbiology
  • Young Adult

Substances

  • Antitubercular Agents

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by National Natural Science Foundation of China No. 82373649, Zhejiang Provincial Natural Science Foundation of China under Grant No. LTGY23H190001, LTGY23H190002, LGF22H260003, Zhejiang Provincial Medical Research Project (grant: 2022KY1189, 2021KY334), Ningbo Top Medical and Health Research Program (No.2023020713). The funder had no role in study design, data collection, analysis, interpretation of data and writing the manuscript.